What is Wedbush’s Estimate for TVTX FY2028 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at Wedbush reduced their FY2028 earnings per share (EPS) estimates for Travere Therapeutics in a report released on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the company will earn $3.79 per share for the year, down from their previous estimate of $3.91. Wedbush has a “Outperform” rating and a $25.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.92) per share.

TVTX has been the topic of several other research reports. Cantor Fitzgerald assumed coverage on Travere Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating on the stock. Barclays upped their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Piper Sandler upped their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Canaccord Genuity Group dropped their price objective on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Finally, Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $27.00 in a research note on Monday, October 21st. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Travere Therapeutics Stock Performance

TVTX opened at $20.31 on Friday. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The business’s 50-day simple moving average is $18.33 and its 200 day simple moving average is $14.91. The firm has a market capitalization of $1.59 billion, a PE ratio of -4.46 and a beta of 0.70. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $21.56.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. During the same quarter in the prior year, the company posted ($1.17) earnings per share. Travere Therapeutics’s revenue was up 69.6% on a year-over-year basis.

Institutional Investors Weigh In On Travere Therapeutics

Large investors have recently modified their holdings of the business. Aigen Investment Management LP acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $170,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $673,000. Millennium Management LLC boosted its holdings in shares of Travere Therapeutics by 33.9% in the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock valued at $24,244,000 after purchasing an additional 747,406 shares in the last quarter. FMR LLC boosted its holdings in shares of Travere Therapeutics by 27.5% in the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock valued at $2,062,000 after purchasing an additional 31,772 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in shares of Travere Therapeutics by 30.2% in the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after purchasing an additional 167,100 shares in the last quarter.

Insider Buying and Selling

In related news, Director Roy D. Baynes sold 16,000 shares of the stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $20.00, for a total transaction of $320,000.00. Following the sale, the director now owns 31,000 shares of the company’s stock, valued at $620,000. This represents a 34.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Eric M. Dube sold 10,736 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $208,922.56. Following the sale, the chief executive officer now directly owns 351,239 shares in the company, valued at $6,835,110.94. This represents a 2.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,143 shares of company stock valued at $1,167,512 over the last 90 days. 3.75% of the stock is owned by corporate insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.